We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
101
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.05M 0.3%
58,750
+5,625
+11% +$260K
ILMN icon
102
Illumina
ILMN
$28.4B
$3.88M 0.28%
18,247
-6,425
-26% -$1.25M
CDTX
103
DELISTED
Cidara Therapeutics
CDTX
$3.5M 0.26%
+12,500
New +$3.84M
FPRX
104
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.98M 0.22%
120,000
-16,000
-12% -$356K
DARE icon
105
Dare Bioscience
DARE
$21M
$2.88M 0.21%
5,208
+708
+16% +$486K
DYAX
106
DELISTED
DYAX CORPORATION
DYAX
$2.72M 0.2%
+102,500
New +$2.72M
INFI
107
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.35M 0.17%
215,000
– –
PTCT icon
108
PTC Therapeutics
PTCT
$6.12B
$2.07M 0.15%
43,000
+2,500
+6% +$146K
TTPH
109
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.04M 0.15%
2,150
-2,975
-58% -$2.43M
XNPT
110
DELISTED
XENOPORT, INC.
XNPT
$1.99M 0.15%
325,000
+15,000
+5% +$98.2K
KIN
111
DELISTED
Kindred Biosciences, Inc.
KIN
$1.88M 0.14%
275,000
– –
AVDL
112
DELISTED
Avadel Pharmaceuticals
AVDL
$1.59M 0.12%
75,000
-385,000
-84% -$6.9M
SCYX icon
113
SCYNEXIS
SCYX
$52M
$1.55M 0.11%
+2,200
New +$1.58M
PBYI icon
114
Puma Biotechnology
PBYI
$454M
$1.28M 0.09%
11,000
-13,250
-55% -$2.4M
FRTX
115
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.28M 0.09%
+581
New +$1.82M
IMDZ
116
DELISTED
Immune Design Corp.
IMDZ
$1.14M 0.08%
+55,000
New +$1.3M
ROKA
117
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$650K 0.05%
25,000
– –
ADVM
118
DELISTED
Adverum Biotechnologies
ADVM
– –
-7,050
Closed -$2.86M
CLLS
119
Cellectis
CLLS
$285M
– –
-75,000
Closed -$2.59M
HRTX icon
120
Heron Therapeutics
HRTX
$92.9M
– –
-32,500
Closed -$473K
LH icon
121
Labcorp
LH
$25.9B
– –
-87,300
Closed -$9.46M
STE icon
122
Steris
STE
$23.1B
– –
-88,000
Closed -$6.18M
XLV icon
123
State Street Health Care Select Sector SPDR ETF
XLV
$42.7B
– –
-110,000
Closed -$7.97M
SRCL
124
DELISTED
Stericycle Inc
SRCL
– –
-73,500
Closed -$10.3M
BNFT
125
DELISTED
Benefitfocus, Inc.
BNFT
– –
-75,000
Closed -$2.76M
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.